{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T08:20:22Z","timestamp":1716020422012},"reference-count":46,"publisher":"Elsevier BV","issue":"38","license":[{"start":{"date-parts":[[2013,8,1]],"date-time":"2013-08-01T00:00:00Z","timestamp":1375315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Public Health Service","award":["AI 046464","AI 070955"],"award-info":[{"award-number":["AI 046464","AI 070955"]}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases, NIH","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000097","name":"National Center for Research Resources, NIH","doi-asserted-by":"crossref","award":["C06 RR 16226"],"award-info":[{"award-number":["C06 RR 16226"]}],"id":[{"id":"10.13039\/100000097","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1016\/j.vaccine.2013.06.009","type":"journal-article","created":{"date-parts":[[2013,6,17]],"date-time":"2013-06-17T06:19:39Z","timestamp":1371449979000},"page":"4192-4199","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["fH-dependent complement evasion by disease-causing meningococcal strains with absent fHbp genes or frameshift mutations"],"prefix":"10.1016","volume":"31","author":[{"given":"Serena","family":"Giuntini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David M.","family":"Vu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan M.","family":"Granoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2013.06.009_bib0005","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1086\/649209","article-title":"Changes in Neisseria meningitidis disease epidemiology in the United States, 1998\u20132007: implications for prevention of meningococcal disease","volume":"50","author":"Cohn","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2013.06.009_bib0010","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1128\/CVI.00529-09","article-title":"Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity","volume":"17","author":"Campbell","year":"2010","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2013.06.009_bib0015","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1574-6976.2006.00053.x","article-title":"Vaccination against meningococcal disease in Europe: review and recommendations for the use of conjugate vaccines","volume":"31","author":"Trotter","year":"2007","journal-title":"FEMS Microbiol Rev"},{"key":"10.1016\/j.vaccine.2013.06.009_bib0020","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1574-6976.2006.00060.x","article-title":"A surveillance network for meningococcal disease in Europe","volume":"31","author":"Trotter","year":"2007","journal-title":"FEMS Microbiol Rev"},{"key":"10.1016\/j.vaccine.2013.06.009_bib0025","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0140-6736(83)90340-9","article-title":"Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis","volume":"2","author":"Finne","year":"1983","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2013.06.009_bib0030","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1001\/jama.2012.85","article-title":"Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial","volume":"307","author":"Gossger","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2013.06.009_bib0035","doi-asserted-by":"crossref","first-page":"e71","DOI":"10.1097\/INF.0b013e3181f59f6d","article-title":"Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial","volume":"29","author":"Snape","year":"2010","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2013.06.009_bib0040","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1086\/656741","article-title":"Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy","volume":"51","author":"Findlow","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2013.06.009_bib0045","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S1473-3099(12)70087-7","article-title":"Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial","volume":"12","author":"Richmond","year":"2012","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2013.06.009_bib0050","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1097\/INF.0b013e31826327e4","article-title":"Safety and immunogenicity of a meningococcal B bivalent rLP2086 vaccine in healthy toddlers aged 18\u201336 months: a phase 1 randomized controlled clinical trial","volume":"31","author":"Marshall","year":"2012","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2013.06.009_bib0055","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1097\/INF.0b013e318282942f","article-title":"European Medicines Agency Recommends Approval of a Broadly Protective Vaccine against Serogroup B Meningococcal Disease","volume":"32","author":"Granoff","year":"2012","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2013.06.009_bib0060","doi-asserted-by":"crossref","first-page":"501","DOI":"10.4049\/jimmunol.177.1.501","article-title":"The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance","volume":"177","author":"Madico","year":"2006","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2013.06.009_bib0065","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1128\/IAI.01191-08","article-title":"Binding of complement factor H (fH) to Neisseria meningitidis is specific for human fH and inhibits complement activation by rat and rabbit sera","volume":"77","author":"Granoff","year":"2009","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2013.06.009_bib0070","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1086\/528994","article-title":"Complement-dependent synergistic bactericidal activity of antibodies against factor H-binding protein, a sparsely distributed meningococcal vaccine antigen","volume":"197","author":"Welsch","year":"2008","journal-title":"J Infect Dis"},{"issue":"Suppl. 8","key":"10.1016\/j.vaccine.2013.06.009_bib0075","doi-asserted-by":"crossref","first-page":"I40","DOI":"10.1016\/j.vaccine.2008.11.060","article-title":"Neisserial pathogenesis","volume":"26","author":"Welsch","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.06.009_bib0080","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1128\/IAI.05604-11","article-title":"Enhanced bacteremia in human factor H transgenic rats infected by Neisseria meningitidis","volume":"80","author":"Vu","year":"2012","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2013.06.009_bib0085","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1084\/jem.20021911","article-title":"Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870","volume":"197","author":"Masignani","year":"2003","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2013.06.009_bib0090","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1128\/CVI.00097-06","article-title":"Rapid genetic grouping of factor H-binding protein (genome-derived neisserial antigen 1870), a promising group B meningococcal vaccine candidate","volume":"13","author":"Beernink","year":"2006","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2013.06.009_bib0095","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1086\/600141","article-title":"Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis","volume":"200","author":"Murphy","year":"2009","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2013.06.009_bib0100","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1128\/CVI.00055-11","article-title":"Characterization of Neisseria meningitidis isolates that do not express the virulence factor and vaccine antigen factor H binding protein","volume":"18","author":"Lucidarme","year":"2011","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2013.06.009_bib0105","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1128\/IAI.00103-12","article-title":"Design of meningococcal factor h binding protein mutant vaccines that do not bind human complement factor h","volume":"80","author":"Pajon","year":"2012","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2013.06.009_bib0110","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1128\/CDLI.5.3.348-354.1998","article-title":"Correlation between serological and sequencing analyses of the PorB outer membrane protein in the Neisseria meningitidis serotyping system","volume":"5","author":"Sacchi","year":"1998","journal-title":"Clin Diagn Lab Immunol"},{"key":"10.1016\/j.vaccine.2013.06.009_bib0115","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1128\/CVI.00211-06","article-title":"Sequencing of the porB gene: a step toward a true characterization of Neisseria meningitidis","volume":"13","author":"Abad","year":"2006","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2013.06.009_bib0120","doi-asserted-by":"crossref","first-page":"5063","DOI":"10.4049\/jimmunol.1103748","article-title":"The relative roles of factor h binding protein, neisserial surface protein a, and lipooligosaccharide sialylation in regulation of the alternative pathway of complement on meningococci","volume":"188","author":"Lewis","year":"2012","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2013.06.009_bib0125","doi-asserted-by":"crossref","first-page":"e1001027","DOI":"10.1371\/journal.ppat.1001027","article-title":"The meningococcal vaccine candidate neisserial surface protein A (NspA) binds to factor H and enhances meningococcal resistance to complement","volume":"6","author":"Lewis","year":"2010","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.vaccine.2013.06.009_bib0130","doi-asserted-by":"crossref","first-page":"3762","DOI":"10.1128\/IAI.69.6.3762-3771.2001","article-title":"Functional activity of anti-neisserial surface protein A monoclonal antibodies against strains of Neisseria meningitidis serogroup B","volume":"69","author":"Moe","year":"2001","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2013.06.009_bib0135","doi-asserted-by":"crossref","first-page":"3751","DOI":"10.1128\/IAI.05182-11","article-title":"Complement-mediated bactericidal activity of anti-factor H binding protein monoclonal antibodies against the meningococcus relies upon blocking factor H binding","volume":"79","author":"Giuntini","year":"2011","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2013.06.009_bib0140","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1128\/jb.173.9.2823-2832.1991","article-title":"Endogenous sialylation of the lipooligosaccharides of Neisseria meningitidis","volume":"173","author":"Mandrell","year":"1991","journal-title":"J Bacteriol"},{"key":"10.1016\/j.vaccine.2013.06.009_bib0145","doi-asserted-by":"crossref","first-page":"5028","DOI":"10.4049\/jimmunol.160.10.5028","article-title":"Bactericidal monoclonal antibodies that define unique meningococcal B polysaccharide epitopes that do not cross-react with human polysialic acid","volume":"160","author":"Granoff","year":"1998","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2013.06.009_bib0150","doi-asserted-by":"crossref","first-page":"6021","DOI":"10.1128\/IAI.70.11.6021-6031.2002","article-title":"Sequential immunization with vesicles prepared from heterologous Neisseria meningitidis strains elicits broadly protective serum antibodies to group B strains","volume":"70","author":"Moe","year":"2002","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2013.06.009_bib0155","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/srep00341","article-title":"A broadly cross-reactive monoclonal antibody against an epitope on the N-terminus of meningococcal fHbp","volume":"2","author":"Vu","year":"2012","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2013.06.009_bib0160","doi-asserted-by":"crossref","first-page":"3606","DOI":"10.4049\/jimmunol.1003470","article-title":"A meningococcal factor H binding protein mutant that eliminates factor H binding enhances protective antibody responses to vaccination","volume":"186","author":"Beernink","year":"2011","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2013.06.009_bib0165","doi-asserted-by":"crossref","first-page":"5903","DOI":"10.1128\/IAI.72.10.5903-5909.2004","article-title":"Naturally acquired passive protective activity against Neisseria meningitidis Group C in the absence of serum bactericidal activity","volume":"72","author":"Welsch","year":"2004","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2013.06.009_bib0170","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/j.1574-6968.2001.tb10675.x","article-title":"Detection of the lst gene in different serogroups and LOS immunotypes of Neisseria meningitidis","volume":"199","author":"Tsang","year":"2001","journal-title":"FEMS Microbiol Lett"},{"key":"10.1016\/j.vaccine.2013.06.009_bib0175","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1006\/mpat.1995.0071","article-title":"Sialylation of neisserial lipopolysaccharide: a major influence on pathogenicity","volume":"19","author":"Smith","year":"1995","journal-title":"Microb Pathog"},{"key":"10.1016\/j.vaccine.2013.06.009_bib0180","doi-asserted-by":"crossref","first-page":"5093","DOI":"10.1016\/j.vaccine.2006.03.091","article-title":"Neisseria meningitidis group B correlates of protection and assay standardization \u2013 international meeting report Emory University, Atlanta, Georgia, United States, 16\u201317 March 2005","volume":"24","author":"Borrow","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.06.009_bib0185","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.tim.2007.03.005","article-title":"Interactions between Neisseria meningitidis and the complement system","volume":"15","author":"Schneider","year":"2007","journal-title":"Trends Microbiol"},{"key":"10.1016\/j.vaccine.2013.06.009_bib0190","doi-asserted-by":"crossref","first-page":"7566","DOI":"10.4049\/jimmunol.176.12.7566","article-title":"Functional significance of factor H binding to Neisseria meningitidis","volume":"176","author":"Schneider","year":"2006","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2013.06.009_bib0195","doi-asserted-by":"crossref","first-page":"16852","DOI":"10.1073\/pnas.1206563109","article-title":"Structural basis for the recognition and cleavage of abasic DNA in Neisseria meningitidis","volume":"42","author":"Lu","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.vaccine.2013.06.009_bib0200","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1111\/j.1462-5822.2012.01838.x","article-title":"Galectin-3 binds Neisseria meningitidis and increases interaction with phagocytic cells","volume":"14","author":"Quattroni","year":"2012","journal-title":"Cell Microbiol"},{"key":"10.1016\/j.vaccine.2013.06.009_bib0205","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1128\/IAI.72.4.2088-2100.2004","article-title":"Vaccine potential of the Neisseria meningitidis 2086 lipoprotein","volume":"72","author":"Fletcher","year":"2004","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2013.06.009_bib0210","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1128\/IAI.01071-08","article-title":"Factor H-binding protein is important for meningococcal survival in human whole blood and serum and in the presence of the antimicrobial peptide LL-37","volume":"77","author":"Seib","year":"2009","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2013.06.009_bib0215","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1128\/IAI.00891-10","article-title":"Characterization of diverse subvariants of the meningococcal factor H (fH) binding protein for their ability to bind fH, to mediate serum resistance, and to induce bactericidal antibodies","volume":"79","author":"Seib","year":"2011","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2013.06.009_bib0220","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1128\/IAI.00849-10","article-title":"Effect of factor H-binding protein sequence variation on factor H binding and survival of Neisseria meningitidis in human blood","volume":"79","author":"Dunphy","year":"2011","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2013.06.009_bib0225","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1128\/IAI.05956-11","article-title":"Combined roles of human IgG subclass, alternative complement pathway activation, and epitope density in the bactericidal activity of antibodies to meningococcal factor h binding protein","volume":"80","author":"Giuntini","year":"2012","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2013.06.009_bib0230","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1099\/jmm.0.46288-0","article-title":"Epidemiology of meningococcal disease in England and Wales 1993\/94 to 2003\/04: contribution and experiences of the Meningococcal reference unit","volume":"55","author":"Gray","year":"2006","journal-title":"J Med Microbiol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X13007780?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X13007780?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,7,2]],"date-time":"2023-07-02T12:08:19Z","timestamp":1688299699000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X13007780"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8]]},"references-count":46,"journal-issue":{"issue":"38","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["S0264410X13007780"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2013.06.009","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2013,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"fH-dependent complement evasion by disease-causing meningococcal strains with absent fHbp genes or frameshift mutations","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2013.06.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}